Skin therapeutics

Abstract

Disclosed herein are methods and compositions for treatment of skin disorders and diseases using botulinum toxin targeted to nerve ganglia.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . A method of smoothing skin and reducing wrinkles in skin, the method comprising applying a therapeutically effective amount of botulinum neurotoxin to nerve ganglia. 
     
     
         21 . The method of  claim 20 , wherein the nerve ganglia is a parasympathetic nerve ganglia. 
     
     
         22 . The method of  claim 20 , wherein the nerve ganglia is a sphenopalatine ganglia, a ciliary ganglia, a submandibular ganglia, superior cervical ganglia, trigeminal ganglia, stellate ganglia and/or an otic ganglia. 
     
     
         23 . The method of  claim 20 , wherein the nerve ganglia is a sphenopalatine ganglia. 
     
     
         24 . The method of  claim 23 , wherein the botulinum neurotoxin is applied to a pterygopalatine fossa. 
     
     
         25 . The method of  claim 20 , wherein the botulinum neurotoxin is applied to the sphenopalatine ganglia. 
     
     
         26 . The method of  claim 25 , wherein the botulinum neurotoxin is applied zygomatically, intranasally, through a hard palate technique, using a high tuberosity approach or combinations thereof. 
     
     
         27 . The method of  claim 20 , wherein the skin pore size is reduced. 
     
     
         28 . The method of  claim 20 , wherein the botulinum neurotoxin is chosen from the group consisting of botulinum neurotoxin type A, botulinum neurotoxin type B, botulinum neurotoxin type C, botulinum neurotoxin type D, botulinum neurotoxin type E, botulinum neurotoxin type F, botulinum neurotoxin type G, and combinations thereof. 
     
     
         29 . The method of  claim 20 , wherein the botulinum neurotoxin is botulinum neurotoxin type A. 
     
     
         30 . The method of  claim 20 , wherein the botulinum neurotoxin is botulinum neurotoxin type B. 
     
     
         31 . The method of  claim 30 , wherein the botulinum neurotoxin type B is administered with epinephrine. 
     
     
         32 . The method of  claim 30 , wherein the botulinum neurotoxin type B further comprises a basic solution. 
     
     
         33 . The method of  claim 20 , wherein the amount of botulinum neurotoxin administered is between about 0.1 to about 1000 units. 
     
     
         34 . The method of  claim 20 , wherein the amount of botulinum neurotoxin administered is between about 5 to about 50 units. 
     
     
         35 . The method of  claim 20 , wherein the botulinum neurotoxin is administered over a period of time. 
     
     
         36 . The method of  claim 20 , wherein the botulinum neurotoxin is administered over one minute. 
     
     
         37 . The method of  claim 20 , wherein the volume of botulinum neurotoxin administered is between 0.1 to 10 cc. 
     
     
         38 . The method of  claim 1 , wherein the botulinum neurotoxin is further administered locally to the skin. 
     
     
         39 .- 57 . (canceled)